TB Archives – Page 15 of 49 – Treatment Action Group

Finally—A New Four-Month Treatment for Drug-Susceptible TB!

October 21, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.

Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos

October 21, 2020
Dorrit Walsh

El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.

Research in Action Awards 2020

October 1, 2020
Dorrit Walsh

Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progress and justice.

Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

September 21, 2020
Dorrit Walsh

This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

September 18, 2020
Dorrit Walsh

Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”

Treatment Action Group Condemns Reported Bullying, Harassment, and Racism at Stop TB Partnership

September 13, 2020
Dorrit Walsh

Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.

TB Research Investments Provide Returns in Combating Both TB and COVID-19

September 4, 2020
Dorrit Walsh

As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and…

Demanding a Higher Standard of TB Care

September 2, 2020
Dorrit Walsh

In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

Treatment Action Group Regrets NYC Health Commissioner Oxiris Barbot’s Resignation

August 6, 2020
Dorrit Walsh

Treatment Action Group, the New York City-based research, policy, and advocacy organization, deplores the August 4, 2020 departure of New York’s Department of Health Commissioner, Dr. Oxiris Barbot, MD.

Letter to Sanofi CEO Calling for Patent Withdrawals on Critical TB Drugs

August 3, 2020
Dorrit Walsh

TAG and our French partners OTMeds (Observatoire de la transparence dans les politiques du médicaments) sent a letter to Sanofi CEO Paul Hudson calling on the company to reverse its efforts to patent two obvious combinations of two critical drugs to prevent tuberculosis: rifapentine and isoniazid.